-
Mashup Score: 4
Data from this proof-of-concept study suggest that combination therapy with guselkumab and golimumab might be more effective for ulcerative colitis than therapy with either drug alone. These findings require confirmation in larger trials.
Categories: Gastroenterology, Latest HeadlinesTweet
-
Mashup Score: 0
CHARLOTTE, N.C. — Guselkumab in combination with golimumab induced greater rates of clinical remission compared with monotherapy among patients with moderate to severely active ulcerative colitis. VEGA phase 2a proof-of-concept week 12 data showed dual blockade of interleukin (IL)-23 and tumor necrosis factor induced clinical response, clinical remission, endoscopic improvement and
Source: www.healio.comCategories: Gastroenterology, Latest HeadlinesTweet-
#VEGA: #Guselkumab plus #golimumab achieved higher clinical remission rates in #UC #ACG2022 #GITwitter #MedTwitter https://t.co/62sM4qOk3E
-
New research - Feagan et al - Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis (#VEGA): a randomised, double-blind, controlled, phase 2, proof-of-concept trial https://t.co/3Q4aVgziie #IBD #gitwitter https://t.co/uzQFXGC39U